CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing AP1189, a new drug for treating rheumatoid arthritis. It aims to activate the body's anti-inflammatory mechanisms, offering a safer and more effective alternative to existing therapies.
Rheumatoid arthritis (RA) is a chronic autoimmune disorder causing inflammation and permanent damage in joints and surrounding tissues - leading to severe disability, decreased quality of life, and reduced life expectancy.
The disease affects more than 6 million people with annual costs amounting to €45billion in the Europe (EU) alone.
There is a wide range of drug therapies for RA, mobilizing a variety of anti-inflammatory and immune modulating effects.
However, a significant proportion (30%) o…
SYNACT PHARMA APS
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
